SDSP (Study Data Standardization Plan) Case Studies and Considerations
Kiran Kumar Kundarapu, Nicole S Gallegos, Merck & Co., Inc., North Wales, PA, USA

ABSTRACT
This poster is intended to cover SDSP case studies focusing on different stages over a drug development lifecycle. Drug development lifecycles and stage gates considered include following 3 phases:

- New Program Phase (pre-IND, IND)
- Retrospective/Ongoing Program Phase (End of phase II/pre-NDA/pre-BLA)
- Already approved /Supplement Program Phase (sNDA/sBLA).

In addition, scenarios where single versus multiple SDSPs for a program will be covered based on IND, population and indication. Additional SDSP topics and considerations will cover:

- Versioning the SDSP covering updates and checks
- Consistency checks between SDSP and other submission documents
- Nuances in CDER and CBER requirements
- CBER Appendix key recommendations for completion
- SDSP Authoring & Reviewing Responsibility Chart

The scope of this poster is to share the data standards information scenarios of SDSP Sections 4 & 5. The PhUSE template and completion guidelines provide clear definition and expectations of other sections of SDSP.

AUTHOR DISCLAIMER
This poster is specific to Merck & Co., Inc., Kenilworth, NJ, USA’s SDSP implementation process, including experiences, and scenarios our company has encountered within their development programs for submission. The experience and scenarios we have encountered with the SDSP is being shared with the hope to benefit others within industry but understand other companies implementing SDSP may have additional considerations, and/or constraints to work with. Our experience is not thought to be the only experience, but one to learn from and allow industry to benefit from.

BACKGROUND/OVERVIEW
The purpose of the Study Data Standardization Plan (SDSP) is to document and communicate a plan for describing the sponsor’s application of data standards in non-clinical and clinical studies across a development program. The SDSP is an important communication tool between the sponsor and the FDA. The SDSP is a living document that assists the FDA in identifying potential data standardization issues early in the development program, may reduce the number of information requests, and clarify previous sponsor / FDA agreements, to provide clarity and prevent filing delays. Additionally, data traceability is improved when submitting an SDSP with the CBER appendix to CBER and/or the OVRR (Office of Vaccines Research and Review) early in vaccine development.

The SDSP has 6 main sections and an appendix (appendix is for CBER submissions only):

- Section 1 - Introduction
- Section 2 - General Sponsor Information
- Section 3 - Product Information
- Section 4 - List of Studies and Standards
- Section 5 - Non-conformance to Supported Standards Justification
- Section 6 - FDA Data Standards Discussions
- Appendix - CBER Appendix
COMMUNICATION OF SDSP WITH FDA AT POTENTIAL STAGE GATES
The diagram shows the SDSP integration into the life cycle of the regulatory IND to NDA submission process including post marketing submission. Timing of the life cycle/flow of drug development is not to the scale.

FIGURE 1. SDSP Communication and Submission

- Recommended initiation at the pre-IND stage of product development.
- Initiation and/or update of the SDSP needs to take place:
  - If a change to the development plan has occurred as defined critical by team that impact SDSP
  - If a stage gate/meeting/filing is approaching (filing of new IND, meetings: pre-IND, End of Phase [EOP] I/II, Pre-Biological License Application [BLA]/Pre-New Drug Application [NDA]), or
  - The SDSP should be reviewed at least annually
- *If not previously shared in any of the stage gates and discussion is needed, a Type C meeting should be requested and communicate SDSP to FDA in the briefing document package to ensure agreement.
- The SDSP should be made available to the FDA at critical stage gate meetings. It is not necessary to share updates with FDA for each update to the SDSP.
- SDSP can be submitted outside of a stage gate with agreement or request from FDA

SDSP SCENARIO FOR NEW PROGRAM PHASE (PRE-IND, IND) AND THINGS TO CONSIDER
- The new program phase is when the SDSP is prepared to submit at the pre-IND meeting; If there is no pre-IND meeting then submit with original IND or as an amendment if the original IND has already been submitted.
- Table 1A displays nonclinical and Table 1B displays planned clinical studies at the time of pre-IND meeting or at IND filing.
- The example (Table 1B) does not include sample Brief Title and Study Design. Refer to PhUSE guidelines for completion instructions.
- At this phase, phase II and III studies may not have started or have been planned.
- The pooled studies information will not be available at this point, mention “NA” in the section 4.3 Pooled Studies. Do not delete empty sections from the template if no content to display.
• List the appropriate data standard versions planned for the studies from the values provided in PhUSE template. If the versions could change by the time the study starts, then it is acceptable to document as TBD (To Be Determined).
• Since the SDSP is a living document, the exchange and terminology standards version could change over the course of the study. It is recommended to start with initial versions and then provide final versions before the Pre-NDA/BLA meeting.
• Items recommended to complete SDSP: protocol, FDA standards catalog, DM plan, clinicaltrials.gov, PhUSE SDSP Completion Guidelines, your company’s adaptation of PhUSE SDSP Template.

Table 1A. Section 4.1 Nonclinical Section from SDSP Template

<table>
<thead>
<tr>
<th>Study Identifier</th>
<th>Brief Title</th>
<th>Study Design</th>
<th>Study Status</th>
<th>Study Start Date</th>
<th>Exchange Standards</th>
<th>Terminology Standards</th>
</tr>
</thead>
</table>

Table 1B Section 4.2 Clinical Studies Section from SDSP Template

<table>
<thead>
<tr>
<th>Study Identifier</th>
<th>Brief Title</th>
<th>Study Design</th>
<th>Study Status</th>
<th>Study Start Date</th>
<th>Exchange Standards</th>
<th>Terminology Standards</th>
</tr>
</thead>
<tbody>
<tr>
<td>AA-11</td>
<td>&lt;an abbreviated summary of the protocol title&gt;</td>
<td>&lt;a brief textual description of the protocol design&gt;</td>
<td>PLANNED</td>
<td>2019-03-16</td>
<td>ADaM v2.1 ADaM IG v1.1 ADaM define.xml v2.0 SDTM v1.4 SDTM IG v3.2 SDTM define.xml 2.0</td>
<td>ADaM CT &lt;TBD&gt; SDTM-CT 2018-03-30 MedDRA V21.0 WHO-DDEHDB3Mar18</td>
</tr>
<tr>
<td>AA-12</td>
<td>&lt;Same as above&gt;</td>
<td>&lt; Same as above&gt;</td>
<td>PLANNED</td>
<td>2020-03-01</td>
<td>TBD</td>
<td>TBD</td>
</tr>
</tbody>
</table>
SDSP FOR RETROSPECTIVE/ONGOING PROGRAMS (EOP II/PRE-NDA/PRE-BLA)

- A retrospective program phase is where the SDSP is initiated and submitted for any of the stage gates after IND submission (End of Phase [EOP]II, Pre-BLA/Pre-ND) and not initiated/submitted during pre-IND/IND stage of development program.
- An ongoing program is where the SDSP was initiated and submitted at the Pre-IND/IND stage gate and updated appropriately for later stage gates after IND.
- Table 2A shows a sample of completed, ongoing and planned studies.
- Table 2B shows a sample of section 5 of the SDSP for submitting non-conformance data standards.
- This is the phase to consider filling in the pooled studies section (4.3) in SDSP if planning to submit ISS/ISE.
- CBER Appendix if submitting to CBER (no later than the EOPII meeting).

Table 2A Section 4.2 Clinical Studies Section from SDSP Template

<table>
<thead>
<tr>
<th>Study Identifier</th>
<th>Brief Title</th>
<th>Study Design</th>
<th>Study Status</th>
<th>Study Start Date</th>
<th>Exchange Standards</th>
<th>Terminology Standards</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABC-11</td>
<td>&lt;an abbreviated summary of the protocol title&gt;</td>
<td>&lt;a brief textual description of the protocol design&gt;</td>
<td>ONGOING</td>
<td>2018-03-16</td>
<td>ADaM v2.1</td>
<td>ADaM CT 2017-09-29</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ADaM IG v1.0</td>
<td>SDTM-CT 2016-03-30</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ADaM define.xml v2.0</td>
<td>MedDRA V21.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SDTM v1.3</td>
<td>WHO-DDEHDB3Mar18</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SDTM IG v3.1.3</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SDTM define.xml 2.0</td>
<td></td>
</tr>
<tr>
<td>ABC-12</td>
<td>&lt; an abbreviated summary of the protocol title &gt;</td>
<td>&lt; a brief textual description of the protocol design &gt;</td>
<td>COMPLETED</td>
<td>2017-03-15</td>
<td>ADaM v2.1</td>
<td>ADaM CT 2016-12-16</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ADaM IG v1.0</td>
<td>SDTM-CT 2016-03-30</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ADaM define.xml v2.0</td>
<td>MedDRA V20.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SDTM v1.1</td>
<td>Sponsor defined drug dictionary</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SDTM IG v3.1.1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SDTM define.xml 2.0</td>
<td></td>
</tr>
<tr>
<td>ABC-13</td>
<td>&lt; same as above&gt;</td>
<td>&lt; same as above&gt;</td>
<td>PLANNED</td>
<td>2020-03-01</td>
<td>TBD</td>
<td>TBD</td>
</tr>
</tbody>
</table>

As per FDA Standard Catalog, SDTM v1.1 and SDTM IG v3.1.1 is not supported by FDA for studies starting on or after 12/17/2016. Therefore, justification should be provided in Section 5.
The Supplement program phase is where the SDSP is initiated for an already approved product for sharing at pre-sNDA/sBLA meeting and at the sNDA/sBLA submission.

- Consider including new trials that were not submitted in the original application, status of trials that were still ongoing from the original program, ongoing studies for which the sponsor plans to submit data for sNDA/sBLA and pooled studies for ISS/ISE if applicable.
- If applicable, include nonclinical studies.
- Follow the sample table referred at new program and ongoing program phase scenario for data standards.

**SDSP FOR ALREADY APPROVED/SUPPLEMENT PROGRAM (sNDA/sBLA)**

- This excerpt from PhUSE SDSP completion guidelines states: “There will be one SDSP per Investigational New Drug (IND) Application; multiple plans are permissible for a single compound in the event of multiple INDs or per communication with the appropriate regulatory agency”.
- Programs with multiple indications or populations (e.g., Adult vs. Pediatric) under the same IND may want to consider having one SDSP per population or per indication. This discussion should be had and agreed upon by SDSP Owners, SDSP Authors, Regulatory Leads in the program and agreement with agency representative.
- If filing under separate INDs, then separate SDSPs are needed.
- Studies supporting multiple filings/submissions can be listed in multiple SDSPs.
- Sub-indications may also have a separate SDSP within a large indication umbrella
  - SDSPs in Oncology are recommended by indication (e.g., HCC, Melanoma, RCC, Endometrial, NSCLC), to support a supplemental indication submission with agreement of agency representative.
  - Merck & Co., Inc., Kenilworth, NJ, USA’s approaching for oncology scopes an SDSP to include only the study data that will be part of a filing that being submitted to meet the objective (NDA/sNDA/BLA/sBLA). In the case of supplements, it is best to limit the SDSP to include only the study data that is subject of that submission.
- A study could be present in more than one SDSP if the study supports the submission across multiple indications.

---

**Table 2B Section 5. Non-Conformance to Supported Standards Justification Section from SDSP Template**

<table>
<thead>
<tr>
<th>Study Identifier</th>
<th>Expected Standard</th>
<th>Provided Standard</th>
<th>Justification for Non-Conformance to Standards (including Exception Information)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABC-12</td>
<td>SDTM v1.3/SEND IG v3.1.3</td>
<td>SDTM v1.1 SDTM IG v3.1.1</td>
<td>Submitted waiver on 03JAN2018; waiver granted on 18JAN2018 &lt;Include justification from waiver submission&gt;</td>
</tr>
</tbody>
</table>

**SINGLE vs MULTIPLE SDSP**

- This excerpt from PhUSE SDSP completion guidelines states: “There will be one SDSP per Investigational New Drug (IND) Application; multiple plans are permissible for a single compound in the event of multiple INDs or per communication with the appropriate regulatory agency”.
- Programs with multiple indications or populations (e.g., Adult vs. Pediatric) under the same IND may want to consider having one SDSP per population or per indication. This discussion should be had and agreed upon by SDSP Owners, SDSP Authors, Regulatory Leads in the program and agreement with agency representative.
- If filing under separate INDs, then separate SDSPs are needed.
- Studies supporting multiple filings/submissions can be listed in multiple SDSPs.
- Sub-indications may also have a separate SDSP within a large indication umbrella
  - SDSPs in Oncology are recommended by indication (e.g., HCC, Melanoma, RCC, Endometrial, NSCLC), to support a supplemental indication submission with agreement of agency representative.
  - Merck & Co., Inc., Kenilworth, NJ, USA’s approaching for oncology scopes an SDSP to include only the study data that will be part of a filing that being submitted to meet the objective (NDA/sNDA/BLA/sBLA). In the case of supplements, it is best to limit the SDSP to include only the study data that is subject of that submission.
- A study could be present in more than one SDSP if the study supports the submission across multiple indications.
VERSIONING THE SDSP COVERING UPDATES AND CHECKS

- When the SDSP needs to be updated, the current version should be changed back to draft in sponsor’s document management tool.
- A best practice is to document the version change history for every update of the SDSP to assist the reviewers, for transparency, and to help with learnings for future programs.
- If a planned study is dropped later in drug development, or a new study is added, the SDSP and version change history should be updated accordingly.

CONSISTENCY CHECKS BETWEEN SDSP AND OTHER SUBMISSION DOCUMENTS

- It is important to ensure the information in SDSP is accurate and consistent among submission documents.
- The following display shows cross checking the data standards information in SDSP with standards data in submission documents.

**Figure 2. Consistency Checks Between SDSP and Submission Documents**

<table>
<thead>
<tr>
<th>SDSP</th>
<th>Submission Documents and Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study Design</td>
<td>Protocol, Clinicaltrials.gov, cSDRG, ADRG</td>
</tr>
<tr>
<td>Study Start Date</td>
<td>TS Domain</td>
</tr>
<tr>
<td>Exchange Standards</td>
<td>cSDRG, ADRG, TS, Define.XML</td>
</tr>
<tr>
<td>Terminology Standards</td>
<td>cSDRG, ADRG, TS, Define.XML, Protocol</td>
</tr>
<tr>
<td>CBER Appendix</td>
<td>SDSP main section, Define.XML, aCRF</td>
</tr>
</tbody>
</table>

NUANCES IN CDER AND CBER REQUIREMENTS

Table 3 is a comparison summary of main differences in submission requirements for SDSP when submitting an SDSP to either CDER or CBER.

**Table 3. CDER vs CBER Requirements**

<table>
<thead>
<tr>
<th>CDER</th>
<th>CBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>• SDSP without CBER Appendix</td>
<td>• SDSP with CBER Appendix</td>
</tr>
<tr>
<td>• Recommended SDSP at Pre-IND/IND</td>
<td>• Annotated CRF recommended after protocol approval</td>
</tr>
<tr>
<td></td>
<td>• Recommended CBER Appendix at Pre-IND/IND or before EOP II meeting</td>
</tr>
</tbody>
</table>
CBER APPENDIX KEY RECOMMENDATIONS FOR COMPLETION

- The CBER appendix includes tables of proposed SDTM domain/variable usage, supplemental domain usage and proposed analysis to aid CBER reviewers.
- The CBER appendix should be submitted well in advance of any licensing application (no later than the EOP II meeting).
- The PhUSE template and completion guidelines provide detailed instructions for completing the CBER appendix section of SDSP.
- Best practice is to ensure consistency of SDTM/ADaM versions, Study ID and Title description between CBER Appendix and SDSP sections 4.2 and 4.3 (if applicable).
- The Sponsor should pay attention to details in the CBER appendix, especially custom domains, and be prepared for questions/comments from CBER reviewers.

SDSP AUTHORING & REVIEWING RESPONSIBILITY CHART

SDSP is a cross-functional effort. The chart (Table 4) may be helpful in identifying authors and reviewers for each section and data standards type from across different functional areas.

<table>
<thead>
<tr>
<th>Roles</th>
<th>NC</th>
<th>DM</th>
<th>DSS</th>
<th>SP&amp;S</th>
<th>REG</th>
<th>CS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sponsor Information</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>A</td>
<td>R</td>
</tr>
<tr>
<td>(Section 2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Product Information</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>A</td>
<td>R</td>
</tr>
<tr>
<td>(Section 3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Non-Clinical</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>R</td>
<td>R</td>
</tr>
<tr>
<td>(Section 4.1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Clinical</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Section 4.2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pooled Studies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Section 4.3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Conformance with</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supported Standards</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Justification**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Section 5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Supported Standards</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discussion**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Section 6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CBER Appendix</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NC:** Nonclinical  
**DM:** Data Management  
**DSS:** Data Standards Specialist  
**SP&S:** Statistical programming & Statisticians  
**CS:** Clinical Scientist  
**REG:** Regulatory  
**A:** Author;  
**C:** Co-Author;  
**R:** Reviewer;  
**N/A:** Not applicable  
**ES:** Exchange Standards  
**TS:** Terminology Standards

REFERENCES

[1] PhUSE CSS Deliverables - SDSP template and completion guidelines  
[https://www.phuse.eu/css-deliverables](https://www.phuse.eu/css-deliverables)  
[3] FDA Standard Catalog  
[https://www.fda.gov/ForIndustry/DataStandards/StudyDataStandards/default.htm](https://www.fda.gov/ForIndustry/DataStandards/StudyDataStandards/default.htm)  
[4] Comparing and Contrasting Differences between the PhUSE SDSP and CBER Checklist  
[5] Touchpoints for the Study Data Standardization Plan  
ACKNOWLEDGEMENT
Ellen Asam
Heather Tiscia
Merck & Co., Inc., Kenilworth, NJ, USA's SDSP SME Team

CONTACT INFORMATION
Kiran K. Kundarapu
Merck & Co., Inc.
351 N. Summneytown Pike
North Wales, PA 19454, USA
(W) 267-305-0711
Kiran.Kundarapu@merck.com

Nicole Gallegos
Merck & Co., Inc.
P.O. BOX 2000
Rahway, NJ 07065, USA
(w)732-594-1106
Nicole.Gallegos2@merck.com